NCT02584842

Rivaroxaban in Endovenous Laser Ablation With and Without Miniphlebectomy

Rivaroxaban for Thrombosis Prophylaxis in Endovenous Laser Ablation With and Without Miniphlebectomy: A Multicenter Experience

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 400 (actual)
• Sponsor: University Hospital, Basel, Switzerland · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine retrospectively if the application of rivaroxaban after endovenous laser ablation with and without miniphlebectomy is safe and if it lowers the risk of venous thrombosis.

Detailed description

Rivaroxaban is an orally active direct factor Xa inhibitor, that is used for thrombosis prophylaxis for example in the setting of orthopaedic surgery. In the observed situation Rivaroxaban was applied in a dosage of 10mg daily during 5 days after endovenous laser ablation.

Conditions

• Varicose Veins
• Venous Thrombosis
• Thromboembolism
• Bleeding

Timeline

• Start date: 2012-01-01
• Primary completion: 2014-12-01
• Completion: 2014-12-01
• First posted: 2015-10-23
• Last updated: 2015-10-23

Locations

1 site across 1 country: Switzerland